Research across Cancer
Related studies from across the Cancer family.
Erdafitinib improves overall survival in FGFR3-altered urothelial carcinoma with HR 0.64 compared to chemotherapy
Trial shows erdafitinib improves survival for specific bladder cancers
In a randomized controlled trial of 266 patients with locally advanced or metastatic urothelial carcinoma and susceptible FGFR3 alterations,…
A new treatment called erdafitinib showed improved survival for patients with specific genetic markers in advanced urothelial carcinoma.
PD-L1 and CTLA-4 Variants Linked to Genitourinary Cancer Risk
Genetic variations linked to risk of certain genitourinary cancers
A meta-analysis of 16 studies links PD-L1 and CTLA-4 variants to altered genitourinary cancer susceptibility, especially in Asian population…
Specific genetic markers in the PD-L1 and CTLA-4 genes are linked to different levels of risk for bladder, kidney, and prostate cancers.
Enfortumab vedotin cutaneous toxicity and peripheral neuropathy are associated with improved outcomes in urothelial carcinoma
Skin Reactions and Nerve Issues Linked to Better Survival
This meta-analysis evaluates the association between enfortumab vedotin-related adverse events and clinical outcomes in patients with advanc…
A review of patients with advanced urothelial carcinoma suggests that certain side effects from enfortumab vedotin may link to improved surv…
Intravesical drug delivery systems improve urothelial drug deposition and allow repurposing of systemic agents
New Delivery Methods May Improve Treatment for Bladder Cancer
This mini review examines intravesical drug delivery systems, including mucoadhesive and targeted platforms, for non-muscle-invasive bladder…
New delivery systems for bladder cancer drugs could help medicine stay in the bladder longer and target cancer cells more effectively.
ADC resistance in bladder cancer is multifactorial, review finds, with no validated overcoming strategy
New research identifies why some bladder cancer drugs stop working
This systematic review examines mechanisms of resistance to antibody-drug conjugates in locally advanced or metastatic urothelial carcinoma.…
Doctors are uncovering the complex reasons why certain bladder cancer treatments lose their power, helping pave the way for more precise the…
Disitamab vedotin and tislelizumab combination achieved remission of skin metastasis in a patient with bladder carcinoma
Drug Combo Clears Skin Metastasis in Bladder Cancer
This case report describes a 70-year-old man with muscle-invasive bladder carcinoma treated with a combination of disitamab vedotin and tisl…
A man's bladder cancer skin spread vanished after a two-drug combo, but it's just one case.
Preoperative inflammatory biomarkers SIRI and NLR associate with worse survival in UTUC after RNU
Inflammatory Biomarkers Linked to Outcomes in Upper Tract Urothelial Carcinoma
This systematic review and meta-analysis of 7,346 patients found that preoperative systemic inflammatory biomarkers, specifically SIRI (HR 2…
Specific inflammatory markers in the blood may be linked to survival outcomes for patients with upper tract urothelial carcinoma.
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection
Cytokine Therapies Show Potential for Treating Canine Cancers
This mini review synthesizes evidence on targeted cytokine delivery platforms, such as IL-12 and IFN-beta, in dogs with various spontaneous …
New research explores how targeted cytokine delivery systems can treat various cancers in dogs and provide data for future human cancer trea…
Liquid biopsy guides kidney-sparing decisions in upper tract urothelial carcinoma without replacing standard care
Liquid biopsy helps doctors decide on kidney-sparing care for upper tract urothelial carcinoma
This review discusses liquid biopsy-guided kidney-sparing management for patients with upper tract urothelial carcinoma. The authors note th…
A review shows liquid biopsy adds value to kidney-sparing decisions for upper tract urothelial carcinoma but does not replace standard imagi…
Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary disease
Doctors found that bladder cancer returning later has higher risk of coming back again
This systematic review and meta-analysis of 1292 patients found that metachronous non-muscle invasive bladder cancer after upper tract uroth…
A large review shows bladder cancer returning after a previous kidney cancer treatment is more likely to grow back. This group also has a lo…
Systematic review of preclinical CBD effects in canine cancers
Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…